科兴水痘减毒活疫苗通过WHO预认证复审

Core Viewpoint - Sinovac Biotech's subsidiary, Sinovac (Dalian) Vaccine Technology Co., has successfully passed the World Health Organization (WHO) pre-certification review for its live attenuated varicella vaccine [1] Group 1 - The successful pre-certification by WHO indicates the vaccine meets international standards for safety and efficacy [1] - This achievement may enhance Sinovac's position in the global vaccine market, particularly in the area of varicella vaccination [1] - The approval could lead to increased demand for the vaccine, potentially boosting the company's revenue and market share [1]